<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04434391</url>
  </required_header>
  <id_info>
    <org_study_id>QF-PCR in GBS screening</org_study_id>
    <nct_id>NCT04434391</nct_id>
  </id_info>
  <brief_title>QF-PCR In GBS Diagnosis During Pregnancy</brief_title>
  <acronym>QFPCRIGDDP</acronym>
  <official_title>Quantitative Fluorescence Polymerase Chain Reaction (QF-PCR) in Group B Strep (GBS) Rectovaginal Colonization Diagnosis During Pregnancy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Estimate the sensitivity and specificity of Quantitative Fluorescence Polymerase Chain&#xD;
      Reaction (QF-PCR) in diagnosing Group B Strep (GBS) rectovaginal colonization during&#xD;
      pregnancy, and follow the outcome of the mothers and infants. According to the outcome of&#xD;
      this study,the investigator wish to determine that wether QF-PCR is an appropriate screening&#xD;
      method for GBS in primary hospitals in China.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a study which include 300 pregnant women who will deliver their babies in PUMCH.&#xD;
&#xD;
        1. Obtain vaginal and rectal swab for Group B Strep (GBS) culture and Quantitative&#xD;
           Fluorescence Polymerase Chain Reaction (QF-PCR) test between 35-37 weeks.&#xD;
&#xD;
        2. Obtain intrauterine swabs of the woman whose vaginal-rectal GBS test is positive,for&#xD;
           both GBS culture and GBS QF-PCR.&#xD;
&#xD;
        3. Obtain rectal and pharynx swabs of the newborns of the woman whose vaginal-rectal GBS&#xD;
           test is positive,for both GBS culture and GBS QF-PCR.&#xD;
&#xD;
        4. Blood test for GBS culture and GBS QF-PCR will be carried out to all the babies&#xD;
           transferred to neonatal intensive care unit(NICU).&#xD;
&#xD;
        5. For all the samples that GBS culture result was not consistent with QF-PCR, We will do&#xD;
           gene sequencing for verification.&#xD;
&#xD;
        6. Pregnant outcome will be followed such as Apgar score,neonatal pneumonia, urinary tract&#xD;
           infection, chorioamnionitis, endometritis,sepsis, and bacteremia,It also can cause focal&#xD;
           infections such as pneumonia, meningitis, and endocarditis.&#xD;
&#xD;
      Inclusion Criteria:&#xD;
&#xD;
      1.Singleton gestation.Pregnant women between 35-37 weeks gestation. 2.22 years of age or&#xD;
      older. 3.Plan to deliver baby in Peking Union Medical College Hospital (PUMCH).&#xD;
&#xD;
      Exclusion Criteria:&#xD;
&#xD;
        1. Preexisting morbidity: Immunocompromised status (HIV +; malignancy; history of organ&#xD;
           transplant; chronic steroid therapy; autoimmune disease requiring treatment during&#xD;
           pregnancy, and other immunocompromised states); Type 1 diabetes and type 2&#xD;
           diabetes;congenital cardiac disease and cardiac valvular disease requiring antibiotic&#xD;
           prophylaxis during procedure/labor; pulmonary disease; renal disease; chronic hepatic&#xD;
           disease; inflammatory bowel disease; stomach or duodenal ulcer; bowel resection, gastric&#xD;
           bypass, and chronic indwelling venous, bladder, or gastric catheter.&#xD;
&#xD;
        2. Multi-fetal gestation.&#xD;
&#xD;
        3. Chronic (daily) use of broad spectrum antibiotics. 4。Prolonged antibiotic use (&gt; 7 days)&#xD;
           in the 4 weeks prior to GBS culture screening.&#xD;
&#xD;
      5.History of infant with GBS sepsis. 6.intrauterine growth retardation(IUGR), Fetal&#xD;
      Anomalies-major diagnosed at time of second trimester anatomy ultrasound.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with positive results of GBS culture or/and QF-PCR</measure>
    <time_frame>3 months</time_frame>
    <description>The percentage will be calculated separately as follows:&#xD;
Number of positive GBS culture from vaginal/rectal swabs in all participants;&#xD;
Number of positive GBS QF-PCR from vaginal/rectal swabs in all participants;&#xD;
Number of positive GBS culture/QF-PCR from intrauterine swabs in women whose vaginal-rectal GBS test is positive;&#xD;
Number of positive GBS culture from pharynx/rectal swabs in newborns whose mother 's vaginal-rectal GBS test is positive;&#xD;
Number of positive GBS QF-PCR from pharynx/rectal swabs in newborns whose mother 's vaginal-rectal GBS test is positive;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse outcomes of pregnancy</measure>
    <time_frame>3 months</time_frame>
    <description>Compare the maternal ante- intra- and postpartum outcomes (urinary tract infections, chorioamnionitis, endometritis, cellulitis, bacteremia, sepsis, and other infectious morbidity) and neonatal outcomes (gestational age at delivery, APGAR scores, bilirubin levels, C-reactive protein, rule out sepsis evaluation, sepsis, pneumonia, meningitis, neonatal ICU admission, and length of hospital stay).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">300</enrollment>
  <condition>GBS</condition>
  <arm_group>
    <arm_group_label>QF-PCR for GBS screening</arm_group_label>
    <description>QF-PCR for vaginal-rectal samples in pregnant women</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>QF-PCR for GBS screening</intervention_name>
    <description>QF-PCR for GBS screening in pregnant women,compared with GBS culture test.</description>
    <arm_group_label>QF-PCR for GBS screening</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1.Singleton gestation.Pregnant women between 35-37 weeks gestation. 2.22 years of age&#xD;
             or older. 3.Plan to deliver baby in PUMCH.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1.Singleton gestation.Pregnant women between 35-37 weeks gestation. 2.22 years of age&#xD;
             or older. 3.Plan to deliver baby in PUMCH.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1.Preexisting morbidity: Immunocompromised status (HIV +; malignancy; history of organ&#xD;
             transplant; chronic steroid therapy; autoimmune disease requiring treatment during&#xD;
             pregnancy, and other immunocompromised states); Type 1 diabetes and type 2&#xD;
             diabetes;congenital cardiac disease and cardiac valvular disease requiring antibiotic&#xD;
             prophylaxis during procedure/labor; pulmonary disease; renal disease; chronic hepatic&#xD;
             disease; inflammatory bowel disease; stomach or duodenal ulcer; bowel resection,&#xD;
             gastric bypass, and chronic indwelling venous, bladder, or gastric catheter.&#xD;
&#xD;
             2.Multi-fetal gestation. 3.Chronic (daily) use of broad spectrum antibiotics.&#xD;
             4.Prolonged antibiotic use (&gt; 7 days) in the 4 weeks prior to GBS culture screening.&#xD;
&#xD;
             5.History of infant with GBS sepsis. 6.IUGR, Fetal Anomalies-major diagnosed at time&#xD;
             of second trimester anatomy ultrasound。 7.Anticipated delivery &lt;35 wks for&#xD;
             maternal/fetal indication 8.Placenta previa or accreta (with anticipated delivery&#xD;
             prior to 35 weeks)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liangkun MA, MD</last_name>
    <role>Study Director</role>
    <affiliation>Peking Union Medical College</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of ob gyn, Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>July 18, 2013</study_first_submitted>
  <study_first_submitted_qc>June 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2020</study_first_posted>
  <last_update_submitted>June 13, 2020</last_update_submitted>
  <last_update_submitted_qc>June 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GBS screening</keyword>
  <keyword>pregnancy outcome</keyword>
  <keyword>QF-PCR</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

